Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPI | P34949 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9294553 | 0.93 | MPI (0.41) | MPI | |
| SCHEMBL5453964 | 0.78 | MPI (0.39) | MPI | |
| SCHEMBL565806 | 0.78 | MPI (0.39) | MPI | |
| SCHEMBL2337805 | 0.78 | MPI (0.39) | MPI | |
| SCHEMBL2889691 | 0.78 | MPI (0.39) | MPI | |
| SCHEMBL4160815 | 0.78 | MPI (0.39) | MPI | |
| SCHEMBL10489052 | 0.78 | MPI (0.39) | MPI | |
| SCHEMBL1586372 | 0.78 | MPI (0.39) | MPI | |
| SCHEMBL459484 | 0.78 | MPI (0.39) | MPI | |
| SCHEMBL458492 | 0.78 | MPI (0.39) | MPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445506-B1 | THE USE OF SPINOSYNS AND SPINOSYN COMPOSITIONS AGAINST DISEASES CAUSED BY PROTOZOANS, VIRAL INFECTIONS AND CANCER | ENTARCO SA (GR) | 2014-12-31 | — | — | EP | claimed |
| EP-1322304-A4 | MANIPULATION OF OXIDATIVE PHOSPHORYLATION FOR HYPERSENSITIZING TUMOR CELLS TO GLYCOLYTIC INHIBITORS | LAMPIDIS THEODORE J (US) | 2008-06-25 | — | — | EP | claimed |
| US-20060025351-A1 | Cancer treatment including glycolytic inhibitors | LAMPIDIS THEODORE J | 2006-02-02 | — | — | US | claimed |
| US-20050043250-A1 | Cancer treatment including glycolytic inhibitors | LAMPIDIS THEODORE J (US) | 2005-02-24 | — | — | US | claimed |
| EP-1322304-A1 | MANIPULATION OF OXIDATIVE PHOSPHORYLATION FOR HYPERSENSITIZING TUMOR CELLS TO GLYCOLYTIC INHIBITORS | Lampidis, Theodore J. (US) | 2003-07-02 | — | — | EP | claimed |
| WO-2001082926-A1 | MANIPULATION OF OXIDATIVE PHOSPHORYLATION FOR HYPERSENSITIZING TUMOR CELLS TO GLYCOLYTIC INHIBITORS | LAMPIDIS THEODORE J (US) | 2001-11-08 | — | — | WO | claimed |
| US-12414934-B2 | Combination therapies | Aardvark Therapeutics, Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| EP-4438734-A2 | REPROGRAMMING OF CELLS TO A NEW FATE | The Scripps Research Institute (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2024137472-A2 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-3399026-B1 | REPROGRAMMING OF CELLS TO A NEW FATE | SCRIPPS RESEARCH INST (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-116139125-A | Combination therapy | 梅制药公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20230137573-A1 | Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent | PROPANC PTY LTD (AU) | 2023-05-04 | — | — | US | disclosed |
| CN-107427003-B | Combination therapy | 梅制药公司 | 2023-01-31 | — | — | CN | disclosed |
| US-6670330-B1 | Treating human breast cancer | LAMPIDIS THEODORE J (US) | 2003-12-30 | — | — | US | disclosed |
| US-20030181393-A1 | Cancer treatment including glycolytic inhibitors | LAMPIDIS THEODORE J (US) | 2003-09-25 | — | — | US | disclosed |
| EP-1322304-A1 | MANIPULATION OF OXIDATIVE PHOSPHORYLATION FOR HYPERSENSITIZING TUMOR CELLS TO GLYCOLYTIC INHIBITORS | Lampidis, Theodore J. (US) | 2003-07-02 | — | — | EP | disclosed |
| WO-2001082926-A1 | MANIPULATION OF OXIDATIVE PHOSPHORYLATION FOR HYPERSENSITIZING TUMOR CELLS TO GLYCOLYTIC INHIBITORS | LAMPIDIS THEODORE J (US) | 2001-11-08 | — | — | WO | disclosed |
| US-4479901-A | Fluorination of carbanions with N-fluoro-N-alkylsulfonamides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-10-30 | — | — | US | disclosed |
| US-4281233-A | Hydrophilic macroporous three dimensional copolymers of hydroxyalkyl acrylates or methacrylates with crosslinking agents and the method of their manufacturing | CESKOSLOVENSKA AKADEMIE VED (CS) | 1981-07-28 | — | — | US | disclosed |
| US-4251634-A | AND REACTION WITH SACCHARIDES USING LEWIS ACID CATALYSTS | CESKOSLOVENSKA AKADEMIE VED (CS) | 1981-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414934-B2 | Combination therapies | PCK2, PDK1, PCK1 | MPI 365/4885 |
| US-20060025351-A1 | Cancer treatment including glycolytic inhibitors | HIF1AN, ALDOA, G6PD | MPI 225/4885 |
| US-20050043250-A1 | Cancer treatment including glycolytic inhibitors | HIF1AN, ALDOA, G6PD | MPI 225/4885 |
| US-20030181393-A1 | Cancer treatment including glycolytic inhibitors | HIF1AN, ALDOA, G6PD | MPI 225/4885 |
| US-20230137573-A1 | Pharmaceutical Composition for Treating Cancer Comprising Trypsinogen and/or Chymotrypsinogen and an Active Agent Selected from a Selenium Compound, a Vanilloid Compound and a Cytoplasmic Glycolysis Reduction Agent | SPINT2, PRSS1, SERPINB1 | MPI 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.